Neuromyelitis optica spectrum disorder (NMOSD), also known as Devic disease, is a chronic disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and the spinal cord (myelitis). Classically, it was felt to be a monophasic illness, consisting of episodes of inflammation of one or both optic nerves and the spinal cord over a short period of time (days or weeks) but, after the initial episode, no recurrence. It is now recognized that most patients satisfying current criteria for NMOSD experience repeated attacks separated by periods of remission. The interval between attacks may be weeks, months or years.
This report contains market size and forecasts of Neuromyelitis Optica Spectrum Disorder (NMOSD) in Global, including the following market information:
Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Neuromyelitis Optica Spectrum Disorder (NMOSD) market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Intravenous Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Neuromyelitis Optica Spectrum Disorder (NMOSD) include F. Hoffmann-La Roche Ltd, Alexion Pharmaceuticals, RemeGen, Nihon Pharmaceutical, Harbour BioMed, Lundbeck, Bionure, Opexa Therapeutics and TG Therapeutics, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Neuromyelitis Optica Spectrum Disorder (NMOSD) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Segment Percentages, by Type, 2021 (%)
Intravenous
Oral
Subcutaneous
Others
Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Segment Percentages, by Application, 2021 (%)
Hospital
Clinic
Others
Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Neuromyelitis Optica Spectrum Disorder (NMOSD) revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Neuromyelitis Optica Spectrum Disorder (NMOSD) revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
F. Hoffmann-La Roche Ltd
Alexion Pharmaceuticals
RemeGen
Nihon Pharmaceutical
Harbour BioMed
Lundbeck
Bionure
Opexa Therapeutics
TG Therapeutics
Bio-Thera Solutions
Boston Pharmaceuticals
Cour Pharmaceutical